MedTrace Logo

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

NCT01260779 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2016-07-11

No results posted yet for this study

Summary

This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable or satisfactory approved alternative therapy and whom, in the opinion of the investigator, may benefit from PV-10 administration.

Conditions

  • Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory
  • Approved Alternative Therapy

Interventions

DRUG

PV-10 (10% rose bengal disodium)

Intralesional injection for chemoablation of cutaneous or subcutaneous lesions

Sponsors & Collaborators

  • Provectus Biopharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01260779 on ClinicalTrials.gov